COVID-19 Immune Phenotyping Programme (CIPP) and COVID National BioResource.
Study code
NBR105
Lead researcher
Professor Christoph Hess
Study type
Samples and data
Institution or company
Cambridge Institute for Therapeutic Immunology and Infectious Disease
Researcher type
Academic
Speciality area
Infection, COVID
Summary
The current COVID-19 pandemic represents a significant threat to public health. At present the underlying disease mechanisms are not well understood. We aim to test the hypothesis that metabolic underpinnings of immune senescence (a dysfunctional state of stable cell cycle arrest that promotes the expression of inflammatory mediators) mediate the severe inflammatory component frequently observed in fatal COVID-19 disease. To test this hypothesis, we propose an integrated approach with potential to rapidly yield (i) biomarkers predicting severe disease, and (ii) a platform for testing the repurposing of approved drugs for cellular metabolic interventions. Together these goals have potential to guide resource allocation and experimental medicine studies.
Participation: For this study, 50 blood samples from COVID-19 BioResource were supplied.
Organisation: This study is organised by Professor Christopher Hess from the Cambridge Institute for Therapeutic Immunology and Infectious Disease
https://www.nature.com/articles/s41590-022-01380-2